Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan

doi:10.3748/wjg.v26.i2.154

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8791)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

447

WORD

277

HTML

3586

Figures (1-2)

394

Tables (1-5)

513

Sum=5217

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

528

Download

917

Sum=1445

Publishing Process of This Article

Item

Count

Browse

748

Download

1381

Sum=2129

Jan 14, 2020 (publication date) through Feb 14, 2025

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jan 14, 2020; 26(2): 154-167
Published online Jan 14, 2020. doi: 10.3748/wjg.v26.i2.154

Table 1 Characteristics and distribution of methylation status in patients with colorectal cancer (n = 120), n (%)

Variables	Total	Methylation status
		*OAF*		≥ 3 of genes¹
		Normal	Tumors	Normal	Tumors
Sex
Male	60 (50.0)	13 (28.9)	28 (62.2)	16 (26.7)	41 (68.3)
Female	60 (50.0)	16 (34.8)	34 (73.9)	19 (31.7)	41 (68.3)
Age in yr at surgery
Mean (SD)	63.8 (14.8)	62.6 (12.6)	63.2 (15.0)	62.5 (13.5)	62.5 (15.3)
< 65	61 (50.8)	15 (30.0)	33 (66.0)	19 (31.1)	45 (73.8)
≥ 65	59 (49.2)	14 (34.1)	29 (70.7)	16 (27.1)	37 (62.7)
Stage
	19 (15.8)	2 (16.7)	6 (50.0)	6 (31.6)	10 (52.6)
	39 (32.5)	6 (20.7)	22 (75.9)	11 (28.2)	26 (66.7)
	40 (33.3)	14 (45.2)	22 (71.0)	11 (27.5)	29 (72.5)
	22 (18.3)	7 (36.8)	12 (63.2)	7 (31.8)	17 (77.3)
Adjuvant chemotherapy
No	32 (28.3)	5 (22.7)	13 (59.1)	13 (40.6)	23 (71.9)
Yes	81 (71.7)	24 (36.9)	46 (70.8)	22 (27.2)	55 (67.9)
Lymph/vascular invasion
No	44 (97.8)	12 (35.3)	21 (61.8)	18 (40.9)	28 (63.6)
Yes	1 (2.2)	0 (0)	1 (100.0)	0 (0)	1 (100.0)
Histological grade²
Well or Moderately	96 (88.9)	23 (31.9)	45 (62.5)	31 (32.3)	62 (64.6)
Poor or undifferentiated	12 (11.1)	5 (45.5)	10 (90.9)	2 (16.7)	11 (91.7)
Tumor location²
Colon	89 (78.8)	19 (28.4)	46 (68.7)	27 (30.3)	59 (66.3)
Rectum	24 (21.2)	10 (50.0)	13 (65.0)	8 (33.3)	19 (79.2)
Progression in 5 yr
No	75 (62.5)	11 (22.0)^a	33 (66.0)	17 (22.7)^a	46 (61.3)
Yes	45 (37.5)	18 (43.9)	29 (70.7)	18 (40.0)	36 (80.0)
All-cause death in 5 yr
No	97 (80.8)	22 (31.0)	50 (70.4)	28 (28.9)	67 (69.1)
Yes	23 (19.2)	7 (35.0)	12 (60.0)	7 (30.4)	15 (65.2)

¹Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF.

²The total number of patients with colorectal cancer does not correspond because of missing data.

^aP < 0.05. OAF: The out at first homolog gene; SD: Standard deviation.

Table 2 Relationship between the number of hypermethylated genes and 5-year time to progression of colorectal cancer patients, n (%)

	Normal tissues						Tumor tissues
	No. of subjects	No. of cases	Crude		Adjusted		No. of subjects	No. of cases	Crude		Adjusted
	No. of subjects	No. of cases	HR	95%CI	HR	95%CI	No. of subjects	No. of cases	HR	95%CI	HR	95%CI
NO. of hypermethylated genes
0	9	3 (33.3)	1.00	Referent	1.00	Referent	3	1 (33.3)	1.00	Referent	1.00	Referent
1	34	8 (23.5)	0.76	0.15-3.74	0.64	0.13-3.23	7	0 (0)	N/A	N/A	N/A	N/A
2	42	16 (38.1)	1.58	0.36-6.94	1.62	0.34-7.62	28	8 (28.6)	0.47	0.05-4.20	0.65	0.07-5.88
3	21	12 (57.1)	2.66	0.58-12.19	2.18	0.46-10.4	39	15 (38.5)	1.02	0.13-7.86	1.36	0.17-10.7
4	11	3 (27.3)	1.28	0.21-7.65	1.48	0.18-12.2	23	14 (60.9)	2.12	0.28-16.3	2.56	0.33-20.2
5	3	3 (100)	7.26^a	1.00-52.84	4.70	0.57-39.0	17	6 (35.3)	1.17	0.14-9.71	1.52	0.17-13.5
6	0	0	N/A	N/A	N/A	N/A	3	1 (33.3)	1.13	0.07-18.0	2.10	0.12-38.3
P value¹				0.02		0.02				0.02		0.02
≥ 3 of genes²	35	18 (51.4)	1.99^a	1.03-3.85	2.01^a	1.00-4.01	82	36(43.9)	3.26^a	1.27-8.39	3.18^a	1.21-8.39

¹P for trend.

²Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF.

^aP < 0.05. Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade, and tumor location. CI: Confidence interval; HR: Hazard ratio; N/A: Not applicable.

Table 3 Relationship between the number of hypermethylated genes and 5-year overall survival of colorectal cancer patients, n (%)

	Normal tissues						Tumor tissues
	No. of subjects	No. of cases	Crude		Adjusted		No. of subjects	No. of cases	Crude		Adjusted
	No. of subjects	No. of cases	HR	95%CI	HR	95%CI	No. of subjects	No. of cases	HR	95%CI	HR	95%CI
NO. of methylated genes
0	9	1 (11.11)	1.00	Referent	1.00	Referent	3	1 (33.33)	1.00	Referent	1.00	Referent
1	34	7 (20.59)	1.52	0.19-12.4	1.19	0.14-10.1	7	0 (0)	N/A	N/A	N/A	N/A
2	42	8 (19.05)	1.76	0.22-14.1	0.89	0.10-8.40	28	7 (25)	0.95	0.12-7.72	0.73	0.08-6.55
3	21	4 (19.05)	1.79	0.20-16.0	1.41	0.15-13.2	39	6 (15.38)	0.66	0.08-5.47	0.59	0.07-5.2
4	11	2 (18.18)	2.11	0.19-23.3	1.40	0.10-18.8	23	6 (26.09)	1.24	0.15-10.3	1.16	0.13-10.2
5	3	1 (33.33)	4.89	0.30-78.8	4.91	0.29-83.4	17	3 (17.65)	0.84	0.09-8.06	0.60	0.05-7.13
6	0	0 (0)	N/A	N/A	N/A	N/A	3	0 (0)	N/A	N/A	N/A	N/A
P value¹				0.33		0.40				0.59		0.64
≥ 3 of genes²	35	7 (20.0)	1.31	0.54-3.18	1.50	0.59-3.81	82	15 (18.3)	1.13	0.48-2.66	1.21	0.47-3.10

Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade and tumor location.

¹P for trend.

²Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF. CI: Confidence interval; HR: Hazard ratio; N/A: Not applicable.

Table 4 Interaction between gene promoter region methylation and different cancer stages for 5-year time to progression of colorectal cancer patients, n (%)

	Normal tissues						Tumor tissues
	No. of subjects	No. of cases	Crude		Adjusted		No. of subjects	No. of cases	Crude		Adjusted
	No. of subjects	No. of cases	HR	95%CI	HR	95%CI	No. of subjects	No. of cases	HR	95%CI	HR	95%CI
OAF
UnMe/local (1 and 2)¹	33	3 (9.1)	1.00	Referent	1.00	Referent	13	0 (0.0)	1.00	Referent	1.00	Referent
UnMe/advanced (3 and 4)²	29	20 (69.0)	14.7^a	3.38-63.6	16.6^a	3.69-74.6	16	12 (75.0)	N/A	N/A	N/A	N/A
Me/local (1 and 2)³	8	0 (0.0)	N/A	N/A	N/A	N/A	28	3 (10.7)	N/A	N/A	N/A	N/A
Me/advanced (3 and 4)⁴	21	18 (85.7)	19.0^a	4.30-84.6	20.3^a	4.12-100	34	26 (76.5)	N/A	N/A	N/A	N/A
P value¹				< 0.01		< 0.01
≥ 3 of genes⁶
UnMe/local (1 and 2)¹	41	2 (4.88)	1.00	Referent	1.00	Referent	22	2 (9.09)	1.00	Referent	1.00	Referent
UnMe/advanced (3 and 4)²	44	25 (56.8)	13.3^a	3.10-57.0	11.9^a	2.72-51.8	16	7 (43.8)	7.17	0.80-64.2	6.56	0.72-59.4
Me/local (1 and 2)³	17	1 (5.88)	N/A	N/A	N/A	N/A	36	1 (2.78)	0.63	0.04-9.99	0.59	0.04-9.62
Me/advanced (3 and 4)⁴	18	17 (94.4)	33.4^a	7.49-149	28.8^a	6.24-133	46	35 (76.1)	23.1^a	3.14-170	20.8^a	2.75-157
P value⁵				< 0.01		< 0.01				< 0.01		< 0.01

¹DNA promoter region unmethylation with cancer stage 1 or 2;

²DNA promoter region unmethylation with cancer stage 3 or 4;

³DNA promoter region methylation with cancer stage 1 or 2;

⁴Me/advanced (3 and 4): DNA promoter region methylation with cancer stage 3 or 4;

⁵P for the joint effect interaction;

⁶Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF.

^aP < 0.05. Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade, and tumor location. CI: Confidence interval; HR: Hazard ratio; OAF: The out at first homolog gene; N/A: Not applicable.

Table 5 Interaction between gene promoter region methylation and different cancer stages for 5-year overall survival of colorectal cancer patients, n (%)

	Normal tissues						Tumor tissues
	No. of subjects	No. of cases	Crude		Adjusted		No. of subjects	No. of cases	Crude		Adjusted
	No. of subjects	No. of cases	HR	95%CI	HR	95%CI	No. of subjects	No. of cases	HR	95%CI	HR	95%CI
OAF
UnMe/local (1 and 2)¹	33	5 (15.2)	1.00	Referent	1.00	Referent	13	2 (15.4)	1.00	Referent	1.00	Referent
UnMe/advanced (3 and 4)²	29	8 (27.6)	2.24	0.73-6.86	4.84^a	1.22-19.2	16	6 (37.5)	3.12	0.63-15.5	15.7^a	1.98-124
Me/local (1 and 2)³	8	2 (25.0)	2.32	0.45-12.0	7.04	0.82-60.4	28	5 (17.9)	1.44	0.28-7.44	3.74	0.54-26.0
Me/advanced (3 and 4)⁴	21	5 (23.8)	1.85	0.53-6.41	5.96^a	1.16-30.6	34	7 (20.6)	1.78	0.37-8.60	6.86	0.93-50.5
P value⁵				0.33		0.03				0.47		0.06
≥ 3 of genes⁶
UnMe/local (1 and 2)¹	41	5 (12.2)	1.00	Referent	1.00	Referent	22	3 (13.6)	1.00	Referent	1.00	Referent
UnMe/advanced (3 and 4)²	44	11 (25.0)	2.57	0.89-7.40	5.28^a	1.35-20.6	16	5 (31.3)	2.68	0.64-11.2	5.53	1.00-30.6
Me/local (1 and 2)³	17	4 (23.5)	2.69	0.72-10.0	4.46	0.93-21.5	36	6 (16.7)	1.59	0.40-6.35	2.04	0.38-11.1
Me/advanced (3 and 4)⁴	18	3 (16.7)	1.86	0.44-7.82	4.27	0.76-23.8	46	9 (19.6)	2.09	0.56-7.76	3.93	0.78-19.8
P value⁵				0.40		0.10				0.27		0.10

¹DNA promoter region unmethylation with cancer stage 1 or 2;

²DNA promoter region unmethylation with cancer stage 3 or 4;

³DNA promoter region methylation with cancer stage 1 or 2;

⁴Me/advanced (3 and 4): DNA promoter region methylation with cancer stage 3 or 4;

⁵P for the joint effect interaction;

⁶Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF.

Citation: Hsu CH, Hsiao CW, Sun CA, Wu WC, Yang T, Hu JM, Huang CH, Liao YC, Chen CY, Lin FH, Chou YC. Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan. World J Gastroenterol 2020; 26(2): 154-167
URL: https://www.wjgnet.com/1007-9327/full/v26/i2/154.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i2.154